Pulmonary complications of inflammatory myopathy

Shelly A. Miller, Marilyn K. Glassberg, Dana P. Ascherman

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Pulmonary complications cause significant morbidity and mortality in the idiopathic inflammatory myopathies. Advances in biomarker discovery have facilitated clinical phenotyping, allowing investigators to better define at-risk patient subsets and to potentially gauge disease activity. This serologic characterization has complemented more traditional assessment tools. Pharmacologic management continues to rely on the use of corticosteroids, often in combination with additional immunosuppressive agents. The rarity of myositis-associated interstitial lung disease and lack of controlled trials have limited analyses of treatment efficacy, mandating the development of standardized outcome measures and improvement of data sharing between disciplines.

Original languageEnglish (US)
Pages (from-to)249-262
Number of pages14
JournalRheumatic Disease Clinics of North America
Issue number2
StatePublished - May 1 2015
Externally publishedYes


  • Autoantibodies
  • Dermatomyositis
  • Inflammatory myopathy
  • Interstitial lung disease (ILD)
  • Polymyositis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Pulmonary complications of inflammatory myopathy'. Together they form a unique fingerprint.

Cite this